Sarepta Therapeutics (SRPT) shares soared 35% in the last trading session to close at $23.77. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.5% loss over the past four weeks.
Sarepta Therapeutics’ stock rallied on positive investor sentiment following early clinical data from two of its siRNA programs, SRP-1001 for facioscapulohumeral muscular dystrophy type I and SRP-1003 for myotonic dystrophy type I. The studies showed dose-dependent muscle delivery, early biomarker activity, and favorable safety profiles. These findings support the potential of the αvβ6 integrin-targeted siRNA platform to improve muscle delivery and overcome key limitations of RNA therapies, reinforcing its promise to transform treatment for these rare genetic disorders.
This biopharmaceutical company is expected to post quarterly earnings of $0.80 per share in its upcoming report, which represents a year-over-year change of +123.4%. Revenues are expected to be $461.22 million, down 38.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Sarepta Therapeutics, the consensus EPS estimate for the quarter has been revised 9.8% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SRPT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Sarepta Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Caribou Biosciences, Inc. (CRBU), another stock in the same industry, closed the last trading session 3.3% higher at $1.88. CRBU has returned -15% in the past month.
Caribou Biosciences' consensus EPS estimate for the upcoming report has changed +7.6% over the past month to -$0.33. Compared to the company's year-ago EPS, this represents a change of +23.3%. Caribou Biosciences currently boasts a Zacks Rank of #2 (Buy).
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report
Caribou Biosciences, Inc. (CRBU): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).